MEDTRONIC DBS THERAPY FOR PARKINSON’S DISEASE

DBS FOR PARKINSON’S  FACT SHEET

Learn more about treatment options, expected results,
and why DBS therapy is an important addition to the
treatment continuum for Parkinson’s disease.
DOWNLOAD FACT SHEET

TREATING THE SYMPTOMS OF PARKINSON'S

Deep brain stimulation (DBS) from Medtronic safely and effectively manages tremor, rigidity, and bradykinesia associated with Parkinson's disease.1 It may be a therapeutic option for patients with recent or longer-standing motor complications.

BENEFITS OF MEDTRONIC DBS

HELPS CONTROL MOTOR FUNCTION AND IMPROVES QUALITY OF LIFE

  • Improves motor function and reduce medication for patients with recent or longer-standing motor complications1,2
  • Improves quality of life and activities of daily living for Parkinson’s patients with recent or longer-standing onset of motor complications.1,2
  • Reduces medication and improves drug-related complications1
  • Offers the first safe* access to MRI anywhere on the body for diagnosing health conditions in patients with deep brain stimulation
  • Allows therapy to be turned off or reversed, preserving options for future therapies and treatments

RISKS

Physicians should be aware that the risks associated with initial surgery may increase with clinical conditions3 such as:

  • Stroke or neurological disorders other than idiopathic Parkinson’s disease
  • Cardiovascular disease
  • Renal or hepatic failure
  • Diabetes mellitus

To help ensure maximum benefits from the neurostimulation system, long-term, post-surgical management of patients is recommended.

The use of Medtronic DBS therapy for Parkinson’s disease has been studied in 6 large randomised control trials (5 level 1). Download our clinical summary to see the data.

Early Intervention to preserve quality of life

Consider deep brain stimulation when a patient has:

  • Symptoms of levodopa-responsive Parkinson's disease of at least 5 years' duration that are not adequately controlled with medication.4,5
  • And motor complications of recent onset (from 4 months to 3 years) or motor complications of longer-standing duration.
graphic showing the effectiveness of Parkinson's disease medication and suggested window for DBS treatment

The Window of opportunity for DBS6

The window of opportunity for your patients to receive DBS therapy begins as early as four years after the appearance of their first Parkinson’s symptoms—so knowing when to have the conversation about further treatment options can make a significant difference in the preservation of your patients’ daily function, and their quality of life.2

Key insights to refer with confidence

Visit the Medtronic EarlyStimulus tool now to find out if your patient may be eligible to begin their DBS journey - before their window of opportunity closes.

Visit Earlystimulus site
Image of male physician in a hospital setting

 

With the guidance of Medtronic’s EarlystimulusTM tool - based on the RAND/UCLA method - you’ll have actionable, objective information at your fingertips to inform the therapeutic decisions you make with your patients.

WATCH NICKI'S STORY

Nicky and her family from the UK show how Medtronic deep brain stimulation therapy has improved their lives.

Medical education For DBS

Access the Medical Education Program for Health Care Professonals in the field of movement disorders and epilepsy.

Visit our Impact site

CONTACT MEDTRONIC

Call UK Technical Services & Mobility Support +44 1923 201 805

*

Medtronic DBS systems are MR Conditional which means they are safe for MRI scans only under certain conditions. If the conditions are not met, the MRI could cause tissue heating, especially at the implanted lead(s) in the brain, which may result in serious and permanent injury or death. Before having an MRI, always talk with the doctor who manages your DBS Therapy to determine your eligibility and discuss potential benefits and risks of MRI. For further information, please call Medtronic at +44 (0) 1923 205101.

1

Medtronic DBS Therapy for Parkinson's Disease and Essential Tremor Clinical Summary, 2015.

2

Schuepbach WMM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med. February 14, 2013; 368:610-622.

3

Fenoy AJ, Simpson RK. Risks of common complications in deep brain stimulation surgery: management and avoidance. J Neurosurg. 2014;120(1):132-139.

4

Parkinson’s UK. “Deep Brain Stimulation for Parkinson’s.” Accessed December 10, 2020. https://www.parkinsons.org.uk/sites/default/files/2020-02/B123_DBS_FINAL_WEB.pdf.

5

Silberstein P, Bittar RG, Boyle R. Deep brain stimulation for Parkinson’s disease: Australian referral guidelines. Journal of Clinical Neuroscience 2009;16:1001-8

6

Okun MS, Foote KD. Parkinson’s disease DBS: what, when, who and why? The time has come to tailor DBS targets. Expert Rev Neurother. 2010 December ; 10(12): 1847–1857”

Brief Statement:

See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. If using an MRI SureScan® device, see the MRI SureScan® technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.